LEPROT and Obesity: Interestingly, GEO2R analysis of GEO GSE27951 data set (from the study; ref. 29) reveals that, among patients with a BMI characterized as overweight (25 < BMI < 30) and those with obesity (30 < BMI < 40), LEPROT levels are upregulated (log [fold change] = 0.614; P = 0.0354) in the SAT of patients with glucose intolerance and T2D (25 < BMI < 40; mean BMI = 33.5; n = 16) compared with patients with normoglycemia who are overweight or are diagnosed with obesity (25 < BMI < 40; mean BMI = 33.3; n = 8).